IP Library Granted Patent US 7,976,848
Granted Patent B2
US 7,976,848 · App. 12/321,797 · Granted Jul 12, 2011

Optimized expression of HPV 58 L1 in yeast

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,848
App. No.
12/321,797
Granted
Jul 12, 2011
Kind
B2
Abstract

Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.

Claims (13)

1. A virus-like particle (VLP) comprising recombinant L1 protein of HPV58, wherein the recombinant L1 protein is produced in yeast and wherein the L1 protein is encoded by a nucleic acid molecule which comprises a sequence of nucleotides as set forth in SEQ ID NO:1.

2. The VLP of claim 1 , wherein the HPV58 L1 nucleic acid molecule consists of a sequence of nucleotides as set forth in SEQ ID NO:1.

3. A pharmaceutical composition comprising the VLPs of claim 2 and a pharmaceutically acceptable carrier.

4. A human papillomavirus (HPV) virus-like particle (VLP) comprising recombinant L1 protein of HPV 58, wherein the recombinant L1 protein comprises a sequence of amino acids as set forth in SEQ ID NO:2.

5. The HPV VLP of claim 4 , wherein the L1 protein consists of a sequence of amino acids as set forth in SEQ ID NO:2.

6. A pharmaceutical composition comprising the HPV VLP of claim 5 and a pharmaceutically acceptable carrier.

7. A method of inducing an immune response in an animal comprising administering the HPV VLP of claim 5 to the animal.

8. A method of producing an HPV58 virus-like particle (VLP), comprising:

(a) transforming a yeast cell with a DNA molecule encoding HPV58 L1 protein, wherein the HPV58 L1 DNA molecule comprises a sequence of nucleotides as set forth in SEQ ID NO:1;

(b) cultivating the transformed yeast cell under conditions that permit expression of the DNA molecule to produce a recombinant papillomavirus protein; and

(c) isolating the recombinant papillomavirus protein to produce the HPV58 VLP.

9. The method of claim 8 wherein the yeast cell is selected from the group consisting of Saccharomyces cerevisiae, Hansenula polymorphs, Pichia pastoris, Kluyveromyces fragilis, Kluyveromyces lactis , and Schizosaccharomyces pombe.

10. The method of claim 9 , wherein the yeast is Saccharomyces cerevisiae.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023845/0940 →